RecruitingNCT06494033

Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients: a Single Center Prospective Study


Sponsor

University of Miami

Enrollment

100 participants

Start Date

Jul 3, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria3

  • Adult patients over 18 years of age
  • Lung transplant candidates with positive CMV IgG
  • Anticipated to receive a lung transplant (both double lung and single lung)

Exclusion Criteria4

  • Negative CMV IgG prior transplant
  • Pregnant or breastfeeding women
  • HIV infected patients
  • Combined organ (e.g., lung-heart, lung-kidney) transplant candidates

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

University of Miami

Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06494033


Related Trials